1 month Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00MarketBeat
HC Wainwright increased their price objective on Ligand Pharmaceuticals from $144.00 to $157.00 and gave the company a “buy” rating in a report on Monday.
XHC Wainwright increased their price objective on Ligand Pharmaceuticals from $144.00 to $157.00 and gave the company a “buy” rating in a report on Monday.
X